Late-Night snacks and booze: a recipe for colon cancer?
NCT ID NCT03955510
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 2 times
Summary
This study looks at how Western habits—like drinking alcohol and eating late—might raise the risk of colorectal cancer. Twelve adults who have had colon polyps in the past will try four different weekly routines, including eating at normal times or late, with or without alcohol. Researchers will take small tissue samples from the colon to see how these habits affect the body's immune response, sleep-wake cycles, and gut bacteria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
12 people
The number who actually took part.
- Started
-
Jul 2016
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults (greater than 21 years old) 2. Have had advanced tubular adenoma within the last year Exclusion Criteria: 1. Asian ethnicity (Due to common polymorphisms of enzymes involved in alcohol metabolism) 2. Does not drink alcohol 3. Alcohol use disorder/Alcohol Abuse 4. A known genetic predisposition to colorectal cancer (FAP, Lynch syndrome) 5. A history of colorectal cancer or inflammatory bowel diseases 6. Presence of comorbidities that might affect the circadian system 1. Chronic renal failure 2. Cirrhosis 3. Advanced neurological conditions (e.g., Parkinson's, MS, epilepsy) 4. Psychological disorders (e.g., PTSD, major depression) 5. Sleep apnea 6. Restless Leg Syndrome 7. Inpatient Status 8. Advanced cardiac failure 9. Night shift workers with active shift work in the past month 10. Planned shift work that will occur during the study 11. Crossed more than two time zones in the previous week 7. Conditions that alter or necessitate a particular eating pattern (e.g., uncontrolled diabetes, eating disorders) 8. Conditions that alter the microbiota (infection or recent history of antibiotic use within three months, or use of pro/prebiotics within one month prior to recruitment) 9. Regular use of medications that can potentially affect melatonin profiles (e.g., Melatonin, Metoclopramide, Psychotropic medications, Hypnotics during the four weeks prior to the study) 10. Any active cancer 11. Inability to sign an informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced tubular adenoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers